LINE in the 13F filings
Lineage Cell Theraputics In · CUSIP 53566V106
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 14 Aug 2025
- latest of these filings; the earliest 6 Aug 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 9 listed it in both
- Shares listed
- 23,830,472
- combined, among listed positions
- Reported value
- $1.0bn
- combined, at the quarter end
Among the 95 comparable managers: 8 buyers (opened or added shares) and 3 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing LINE in Q2 2025
11 of 11 holders
Largest increases and reductions, by shares
Increases
- D1 Capital Partners LPexisting position · 4,622,594 shares now+2,165,533
- Capital Research Global Investorsexisting position · 3,032,333 shares now+1,031,496
- Artisan Partners LPexisting position · 622,883 shares now+81,159
- Eisler Capital Management Ltdnew position · 69,536 shares now+69,536
- Holocene Advisors LPexisting position · 106,450 shares now+58,300
Reductions
- T. Rowe Price Associates Incexisting position · 3,837,816 shares now-526,881
- Janus Henderson Group Ltdexisting position · 3,216,943 shares now-411,211
- Capital World Investorsexisting position · 4,822,584 shares now-335,334
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 16 | $1.5bn | 16 | 0 |
| Q4 2024 | 12 | $1.1bn | 9 | 7 |
| Q1 2025 | 9 | $1.3bn | 6 | 3 |
| Q2 2025 | 11 | $1.0bn | 8 | 3 |
| Q3 2025 | 7 | $646m | 4 | 4 |
| Q4 2025 | 6 | $481m | 13 | 12 |
| Q1 2026 | 4 | $341m | 13 | 12 |
| Q2 2026 | 4 | $513m | 9 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LINE and WELL →LINE and EQIX →LINE and PLD →Choose a stock to compare with LINE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LINE, latest filings →Back to the 13F Explorer →